Mechanistic studies on Listeria infection and inhibition of allograft tolerance
李斯特菌感染及抑制同种异体移植耐受的机制研究
基本信息
- 批准号:7901592
- 负责人:
- 金额:$ 37.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-15 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AlloantigenAllograft ToleranceAllograftingBacteriaBacterial InfectionsBacterial ModelCD8-Positive T-LymphocytesCellsDevelopmentEventExposure toGoalsGraft RejectionGuanine Nucleotide Dissociation InhibitorsHeartHeart TransplantationImmune responseImmune systemImmunoglobulin GInfectionInfection preventionInvestigationKidneyListeria monocytogenesListeriosisLungMaintenanceMediatingModelingMonoclonal AntibodiesMusOrganOrgan TransplantationPreventionProductionResistanceRoleSkinSmall IntestinesSpleenT-LymphocyteTestingTimeTransfusionTransplantationbaseimmunogenicimmunogenicityinsightnovel strategiespathogenprevent
项目摘要
DESCRIPTION (provided by applicant): Transplanted organs such as the skin, lung and small bowel are more immunogenic and more resistant to tolerance induction than the heart and kidney. We reasoned that transplantation of the former organs would more likely result in the concurrent exposure of the immune system to bacteria and alloantigens than would transplantation of the latter. Based on that, we hypothesized that the concomitant exposure to bacteria enhances the immune response to the allograft and prevents allograft tolerance. As a proof of principle, we tested the effect of a model bacterial infection on the development and maintenance of allograft tolerance. Our preliminary observations indicate that Listeria monocytogenes (LM) infection at the time of heart transplantation prevented the development of tolerance in mice receiving anti-CD154 monoclonal antibodies (anti-CD154) ¿ donor-specific transfusion (DST). The rejection in LM-infected and anti-CD154 ¿ DST- treated recipients was associated with the production of allo-IgG and primed, alloreactive IFN?-producing cells in the spleen. The effect of LM was observed in either CD4- or CD8-deficient mice, suggesting that LM infection independently facilitated the priming of alloreactive CD4+ and CD8+ cells. We also observed that LM infection on days 60-90 post-transplantation reversed allograft tolerance induced by anti-CD154 ¿ DST. However, the rejection of long-term surviving allografts was not associated with the production of allo-IgG or the presence of primed, alloreactive IFN?-producing cells in the spleen. These observations led us to hypothesize that the mechanisms by which LM infection reverses established tolerance differ from the mechanisms by which LM prevents the induction of tolerance. This proposal aims at further defining the mechanisms by which LM infection antagonizes the development and maintenance of allograft tolerance. We have proposed two aims: 1: Delineate the mechanisms by which LM infection prevents anti-CD154-mediated induction of tolerance. 2: Delineate the mechanisms by which LM infection precipitates the rejection of tolerant allografts. While these investigations use LM as a model bacterial pathogen and anti-CD154 as the model agent for inducing tolerance, we believe that the insights gained from these studies will likely be applicable to other pathogens and models of allograft tolerance. The long-term goal of these investigations is to use the information gained from these studies to develop new approaches for reducing the immunogenicity of transplanted organs, and for facilitating the induction and maintenance of allograft tolerance.
描述(由申请方提供):与心脏和肾脏相比,皮肤、肺和小肠等移植器官的免疫原性更强,对耐受诱导的抗性更强。我们推断,前一种器官的移植比后一种器官的移植更可能导致免疫系统同时暴露于细菌和同种异体抗原。基于此,我们假设,同时暴露于细菌增强了对同种异体移植物的免疫反应,并防止了同种异体移植物耐受。作为原理的证明,我们测试了模型细菌感染对同种异体移植物耐受性的发展和维持的影响。我们的初步观察表明,心脏移植时单核细胞增生李斯特菌(LM)感染阻止了接受抗CD 154单克隆抗体(抗CD 154)和供体特异性输血(DST)的小鼠产生耐受性。在LM感染和抗CD 154 <$DST治疗的受者中,排斥反应与异源IgG和致敏同种异体反应性IFN?在脾脏中产生细胞。在CD 4-或CD 8-缺陷小鼠中观察到LM的作用,表明LM感染独立地促进同种异体反应性CD 4+和CD 8+细胞的引发。我们还观察到移植后60-90天的LM感染逆转了抗CD 154 <$DST诱导的同种异体移植物耐受。然而,长期存活的同种异体移植物的排斥反应与异源IgG的产生或致敏的同种异体反应性IFN?在脾脏中产生细胞。这些观察结果使我们假设LM感染逆转已建立的耐受性的机制不同于LM阻止诱导耐受性的机制。该建议旨在进一步确定LM感染拮抗同种异体移植耐受的发展和维持的机制。我们提出了两个目标:1:阐明LM感染阻止抗CD 154介导的耐受诱导的机制。2:阐明LM感染加速耐受同种异体移植物排斥反应的机制。虽然这些研究使用LM作为模型细菌病原体和抗CD 154作为诱导耐受的模型药物,但我们相信从这些研究中获得的见解可能适用于其他病原体和同种异体移植物耐受模型。这些研究的长期目标是利用从这些研究中获得的信息开发新的方法来降低移植器官的免疫原性,并促进诱导和维持同种异体移植耐受。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anita S Chong其他文献
Anita S Chong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anita S Chong', 18)}}的其他基金
Intrarenal B cells in acute kidney allograft rejection
肾内 B 细胞在急性同种肾移植排斥反应中的作用
- 批准号:
10543172 - 财政年份:2020
- 资助金额:
$ 37.27万 - 项目类别:
Intrarenal B cells in acute kidney allograft rejection
肾内 B 细胞在急性同种肾移植排斥反应中的作用
- 批准号:
9980656 - 财政年份:2020
- 资助金额:
$ 37.27万 - 项目类别:
Intrarenal B cells in acute kidney allograft rejection
肾内 B 细胞在急性同种肾移植排斥反应中的作用
- 批准号:
10329990 - 财政年份:2020
- 资助金额:
$ 37.27万 - 项目类别:
Impact of Infections on the Stability of Established Tolerance
感染对既定耐受稳定性的影响
- 批准号:
8512661 - 财政年份:2013
- 资助金额:
$ 37.27万 - 项目类别:
相似海外基金
Targeting innate immunity for induction of robust renal allograft tolerance
针对先天免疫诱导强大的肾同种异体移植耐受
- 批准号:
10622050 - 财政年份:2023
- 资助金额:
$ 37.27万 - 项目类别:
Novel Approaches to Inducing Lung Allograft Tolerance in NHPs
诱导 NHP 肺同种异体移植耐受的新方法
- 批准号:
10622123 - 财政年份:2023
- 资助金额:
$ 37.27万 - 项目类别:
Project 1: Next Generation Mixed Chimerism Strategies to Induce Lung Allograft Tolerance in NHPs
项目 1:诱导 NHP 肺同种异体移植耐受的下一代混合嵌合策略
- 批准号:
10622127 - 财政年份:2023
- 资助金额:
$ 37.27万 - 项目类别:
Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates
在非人灵长类动物中抑制 Bcl-2 和 Mcl-1 可诱导造血嵌合和肾同种异体移植耐受,而无需骨髓抑制
- 批准号:
10634698 - 财政年份:2022
- 资助金额:
$ 37.27万 - 项目类别:
Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft Tolerance
项目 3:增强共刺激阻断以实现临床相关的同种异体移植心脏耐受性
- 批准号:
10457402 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别:
New Approaches to Inducing Cardiac Allograft Tolerance
诱导心脏同种异体移植耐受的新方法
- 批准号:
10673071 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别:
New Approaches to Inducing Cardiac Allograft Tolerance
诱导心脏同种异体移植耐受的新方法
- 批准号:
10457397 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别:
New Approaches to Inducing Cardiac Allograft Tolerance
诱导心脏同种异体移植耐受的新方法
- 批准号:
10270357 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别:
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance
项目 2:用于心脏同种异体移植耐受的下一代混合嵌合诱导
- 批准号:
10270361 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别:
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance
项目 2:用于心脏同种异体移植耐受的下一代混合嵌合诱导
- 批准号:
10457401 - 财政年份:2021
- 资助金额:
$ 37.27万 - 项目类别: